Cingulate Inc
CINGHealthcare·Biotechnology·USA·Micro·NASD·Nov 12 • 3:59 PM ET
4.49-0.15 (-3.23%)
2026-11-13 13:10 CET
Market cap
$65.29M
Revenue, TTM
0.00 USD m
Net income, TTM
-28.81 USD m
Free cash flow, TTM
-20.94 USD m
EPS diluted, TTM
-3.62
Price
CING against its 20, 50 and 200-day averagesPatternshover a marker to name it
62.2% under the 52-week high of 11.89 on 17 Mar 2026. 52-week low 3.16 on 1 Jun 2026. Last 15 sessions, 34.5% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 14
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
CING52-week range, 15% of the way up
3.1611.89
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.
| Employees | 14 |
|---|---|
| IPO | Dec 08, 2021 |
| Beta | -0.88 |
| ATR, 14d | 0.30 |
| Rel volume | 0.00 |
| Short float | 8.55% |
| Insider own | 16.53% |
| Inst own | 13.82% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $65.29M |
| Enterprise Value | 43.18M |
| Income | -28.81M |
| Sales | 0.00M |
| Book / share | 1.69 |
| Cash / share | 1.95 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 14 |
| IPO | Dec 08, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 2.66 |
| Price / cash | 2.30 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 3.50 |
| Current Ratio | 3.50 |
| Debt / equity | 0.27 |
| Long-term debt / equity | 0.04 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -3.62 |
|---|---|
| Earnings next year | -1.75 |
| Earnings next quarter | -0.43 |
| Earnings this year | 51.97% |
| Earnings next year | 17.82% |
| Earnings growth, 5 years | 35.89% |
| Past earnings growth | 77.21% 50.70% |
| Past sales growth | - - |
| Earnings vs last year | 37.29% |
| Sales vs last year | - |
| Earnings vs last quarter | 59.19% |
| Sales vs last quarter | - |
| Earnings | Aug 13 BMO |
| Surprise | 28.00% - |
Ownership
| Insiders own | 16.53% |
|---|---|
| Insider trades | 4.22% |
| Institutions own | 13.82% |
| Institution trades | 3.47% |
| Return on assets | -123.76% |
| Return on equity | -198.74% |
| Return on capital | -117.85% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -5.10% |
| 50-day average | -7.81% |
| 200-day average | -16.82% |
Technical
| Shares out | 13.89M |
|---|---|
| Shares floating | 12.14M |
| Short / float | 8.55% |
| Short ratio | 8.63 |
| Short interest | 1.04M |
| 52-week high | 11.89 -62.2% |
| 52-week low | 3.16 +42.1% |
| Volatility | 6.27% 6.71% |
| Average range | 0.30 |
| Strength index | 43.44 |
| Market sensitivity | -0.88 |
| Relative volume | 0.00 |
| Avg Volume | 120.17K |
| Volume | 0 |
Performance
| Perf Week | 5.90% |
|---|---|
| Perf Month | -1.75% |
| Perf Quarter | -11.79% |
| Perf Half Y | 2.28% |
| Perf YTD | 3.46% |
| Perf Year | 18.16% |
| Perf 3Y | -94.06% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 21.50 |
| Prev Close | 4.49 |
| Price | 4.49 |
| Change % | 0.00% |
Analyst ratings
latest 2 of 2| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jan 10, 2025 | Initiated | ROTH MKM | Buy | $12 | +167.3% |
| Dec 22, 2023 | Downgrade | Laidlaw | Buy → Hold |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| AYTU | Aytu BioPharma Inc | 19.45M |
| COLL | Collegium Pharmaceutical Inc | 775.33M |
| ZVRA | Zevra Therapeutics Inc | 609.92M |
| SUPN | Supernus Inc | 6.07B |
| AXSM | Axsome Therapeutics Inc | 7.59B |
| NRXP | NRX Pharmaceuticals Inc | 99.51M |
| TNXP | Tonix Pharmaceuticals Holding Corp | 62.77M |
| VTGN | Vistagen Therapeutics Inc | 7.98M |
| LPCN | Lipocine Inc | 17.94M |
| NBIX | Neurocrine Biosciences Inc | 17.31B |
Insider trading
5 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Hargroves Thomas Jeffrey | Director | Feb 13 '26 | Buy | 5.04 | 97,276 | 490,271 | 97,468 | Jun 08 07:02 PM |
| Werth Peter J. | Director | Feb 06 '26 | Buy | 5.04 | 19,455 | 98,053 | 117,449 | Feb 10 07:00 PM |
| Callahan Jennifer L. | SVP and CFO | Feb 06 '26 | Buy | 5.04 | 4,864 | 24,515 | 5,059 | Feb 10 07:00 PM |
| Schaffer Shane J. | Chief Executive Officer | Feb 06 '26 | Buy | 5.04 | 6,809 | 34,317 | 10,175 | Feb 10 07:00 PM |
| Brams Matthew | EVP and Chief Medical Officer | Feb 06 '26 | Buy | 5.04 | 1,946 | 9,808 | 4,656 | Feb 10 07:00 PM |
Held by
AUMNews
latest 14 of 200- Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King (GlobeNewswire)
- Shane Schaffer, Cingulate Chairman & CEO to Present "SMART Launch" Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma (GlobeNewswire)
- Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness (GlobeNewswire)
- Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile (GlobeNewswire)
- Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology (GlobeNewswire) +5.19%
- Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E (GlobeNewswire) -8.66%
- Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 (GlobeNewswire)
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 (Newsfile) -6.35%
- Cingulate Receives Complete Response Letter from FDA for CTx-1301 (GlobeNewswire) +11.94%
- Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301 (GlobeNewswire) -10.77%
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 (Newsfile)
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (GlobeNewswire) -31.05%
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
- Cingulate price target lowered to $16 from $17 at Roth Capital (TipRanks)
Quarterly earnings
2026Q2 EPS -0.450 beat -0.625, from -1.038 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-13 08:30 | -0.450 | -0.625 | -0.450 | 0.00 | 0.00 | EPS -28.0% · sales - | vs 2025Q2, year-ago quarter · EPS -56.6% · sales - | 6 EPS · 5 sales | Open -4.80% vs SPY +0.31%. Close -4.22% vs SPY +0.70% |
| 2026Q1ended 2026-03-31 | 2026-05-14 08:30 | -0.950 | -0.520 | -0.954 | 0.00 | 0.00 | EPS +82.7% · sales - | vs 2025Q1, year-ago quarter · EPS -8.7% · sales - | 4 EPS · 2 sales | Open -4.27% vs SPY +0.18%. Close -10.77% vs SPY +0.79% |
| 2025Q4ended 2025-12-31 | 2026-03-18 08:30 | -0.974 | -0.632 | -0.865 | 0.00 | 0.00 | EPS +54.1% · sales - | vs 2024Q4, year-ago quarter · EPS -47.4% · sales - | 5 EPS · 3 sales | Open -5.49% vs SPY -0.36%. Close -31.05% vs SPY -1.40% |
| 2025Q3ended 2025-09-30 | 2025-11-13 08:30 | -1.350 | -0.880 | -1.352 | 0.00 | 0.00 | EPS +53.4% · sales - | vs 2024Q3, year-ago quarter · EPS -26.2% · sales - | 4 EPS · 2 sales | Open -0.53% vs SPY -0.42%. Close -12.37% vs SPY -1.66% |
| 2025Q2ended 2025-06-30 | 2025-08-19 12:00 | -1.038 | -0.915 | -1.091 | 0.00 | 0.00 | EPS +13.4% · sales - | vs 2024Q2, year-ago quarter · EPS -81.0% · sales - | 4 EPS · 2 sales | Open -0.24% vs SPY -0.03%. Close -9.62% vs SPY -0.54% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -1.040 | -1.008 | -1.043 | 0.00 | 0.00 | EPS +3.2% · sales - | vs 2024Q1, year-ago quarter · EPS -85.6% · sales - | 4 EPS · 2 sales | Open -1.22% vs SPY +0.25%. Close -1.96% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-26 16:30 | -1.853 | -1.375 | -1.802 | 0.00 | 0.00 | EPS +34.8% · sales - | vs 2023Q4, year-ago quarter · EPS -96.9% · sales - | 4 EPS · 2 sales | Open +1.45% vs SPY -0.25%. Close +5.07% vs SPY -0.27% |
| 2024Q3ended 2024-09-30 | 2024-11-08 08:30 | -1.830 | -2.363 | -1.830 | 0.00 | 0.00 | EPS -22.6% · sales - | vs 2023Q3, year-ago quarter · EPS -97.5% · sales - | 3 EPS · 2 sales | Open -4.36% vs SPY +0.09%. Close +0.87% vs SPY +0.43% |
| 2024Q2ended 2024-06-30 | 2024-08-13 08:30 | -5.470 | -5.640 | -5.474 | 0.00 | 0.00 | EPS -3.0% · sales - | vs 2023Q2, year-ago quarter · EPS -96.0% · sales - | 2 EPS · 1 sales | Open +2.80% vs SPY +0.61%. Close -21.06% vs SPY +1.64% |
| 2024Q1ended 2024-03-31 | 2024-05-08 08:30 | -7.200 | -13.980 | -7.213 | 0.00 | 0.00 | EPS -48.5% · sales - | vs 2023Q1, year-ago quarter · EPS -91.4% · sales - | 2 EPS · 1 sales | Open +3.76% vs SPY -0.36%. Close +0.15% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-04-01 08:30 | -59.100 | -58.320 | -71.276 | 0.00 | 0.00 | EPS +1.3% · sales - | vs 2022Q4, year-ago quarter · EPS -39.9% · sales - | 4 EPS · 1 sales | Open +0.91% vs SPY +0.15%. Close -0.91% vs SPY -0.17% |
| 2023Q3ended 2023-09-30 | 2023-11-13 16:30 | -72.000 | -88.800 | -72.595 | 0.00 | 0.00 | EPS -18.9% · sales - | vs 2022Q3, year-ago quarter · EPS -16.7% · sales - | 4 EPS · 1 sales | Open 0.00% vs SPY +1.39%. Close -3.23% vs SPY +1.94% |
| 2023Q2ended 2023-06-30 | 2023-08-14 16:30 | -136.8 | -84.800 | -135.78 | 0.00 | 0.00 | EPS +61.3% · sales - | vs 2022Q2, year-ago quarter · EPS +58.3% · sales - | 3 EPS · 1 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-10 16:30 | -84.000 | -75.600 | -84.989 | - | - | EPS +11.1% · sales - | vs 2022Q1, year-ago quarter · EPS -20.5% · sales - | 2 | - |
| 2022Q4ended 2022-12-31 | 2023-03-10 16:30 | -98.400 | -89.400 | -97.726 | - | 0.00 | EPS +10.1% · sales - | vs 2021Q4, year-ago quarter · EPS +28.1% · sales - | 4 EPS · 1 sales | - |
| 2022Q3ended 2022-09-30 | 2022-11-14 08:30 | -86.400 | -88.800 | -85.464 | 0.00 | 0.00 | EPS -2.7% · sales - | vs 2021Q3, year-ago quarter · EPS -73.9% · sales - | 2 EPS · 1 sales | - |
Annual earnings
2025FY EPS -4.433 missed -3.820, from -9.738 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.660 | - | - | 44.56 | 6.80 |
| 2029FYestimate | - | -0.410 | - | - | 25.47 | - |
| 2028FYestimate | - | -1.170 | - | - | 32.96 | - |
| 2027FYestimate | - | -1.753 | - | - | 12.17 | - |
| 2026FYestimate | - | -2.133 | - | - | 0.00 | - |
| 2025FY | -4.433 | -3.820 | -4.390 | 0.00 | 0.00 | - |
| 2024FY | -9.738 | -9.435 | -10.860 | 0.00 | 0.00 | - |
| 2023FY | -312 | -333.21 | -311.99 | 0.00 | 0.00 | - |
| 2022FY | -374.4 | -364.2 | -375.11 | 0.00 | 0.00 | - |
| 2021FY | -669.6 | -265.2 | -439.49 | - | 0.00 | - |
Quarterly results
2026Q2 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.13 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-04 | -2.13 | 0.0% |
| 2026Q3 | E | per share | 2026-11-04 | -0.43 | 0.0% |
| 2026FY | R | per share | 2026-10-27 | -1.91 | 0.0% |
| 2026Q3 | R | per share | 2026-10-27 | -0.39 | 0.0% |
| 2026FY | S | per share | 2026-09-11 | 0.00 | - |
| 2026Q3 | S | per share | 2026-09-11 | 0.00 | - |
| 2026Q2 | E | per share | 2026-08-13 | -0.60 | -4.0% |
| 2026Q2 | R | per share | 2026-08-13 | -0.45 | -25.0% |
| 2026Q2 | S | per share | 2026-06-02 | 0.00 | - |
| 2026Q1 | E | per share | 2026-05-15 | -0.53 | -7.6% |
| 2026Q1 | R | per share | 2026-05-14 | -0.70 | +40.0% |
| 2026Q1 | S | per share | 2026-04-07 | 0.00 | - |
| 2025FY | E | per share | 2026-03-06 | -4.19 | +9.6% |
| 2025Q4 | E | per share | 2026-03-06 | -0.75 | +18.7% |
| 2025FY | S | per share | 2026-03-06 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-06 | 0.00 | - |
| 2025FY | R | per share | 2026-01-28 | -4.14 | 0.0% |
| 2025Q4 | R | per share | 2026-01-28 | -0.92 | 0.0% |
| 2025Q3 | E | per share | 2025-11-18 | -0.99 | +12.8% |
| 2025Q3 | R | per share | 2025-11-03 | -0.87 | 0.0% |
| 2025Q2 | E | per share | 2025-08-21 | -0.96 | -7.2% |
| 2025Q2 | R | per share | 2025-08-20 | -0.88 | -11.1% |
| 2025Q3 | S | per share | 2025-08-19 | 0.00 | - |
| 2025Q2 | S | per share | 2025-05-09 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-17 | -1.01 | -0.2% |
| 2025Q1 | S | per share | 2025-04-17 | 0.00 | - |
| 2025Q1 | R | per share | 2025-04-02 | -1.02 | - |
| 2024FY | E | per share | 2025-03-25 | -10.31 | 0.0% |
| 2024Q4 | E | per share | 2025-03-25 | -1.53 | 0.0% |
| 2024FY | R | per share | 2025-02-02 | -6.81 | 0.0% |
| 2024Q4 | R | per share | 2025-02-02 | -0.92 | 0.0% |
| 2024FY | S | per share | 2025-01-08 | 0.00 | - |
| 2024Q4 | S | per share | 2025-01-08 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-27 | -2.36 | 0.0% |
| 2024Q3 | R | per share | 2024-10-27 | -2.65 | 0.0% |
| 2024Q3 | S | per share | 2024-08-30 | 0.00 | - |
| 2024Q2 | E | per share | 2024-07-23 | -5.64 | 0.0% |
| 2024Q2 | R | per share | 2024-07-23 | -6.36 | 0.0% |
| 2024Q2 | S | per share | 2024-05-08 | 0.00 | - |
| 2024Q1 | E | per share | 2024-04-24 | -1.17 | -9.7% |
| 2024Q1 | S | per share | 2024-04-24 | 0.00 | - |
| 2024Q1 | R | per share | 2024-04-03 | -1.29 | -74.2% |
| 2023FY | E | per share | 2024-03-19 | -27.77 | 0.0% |
| 2023FY | R | per share | 2024-01-29 | -29.71 | 0.0% |
| 2023FY | S | per share | 2023-07-06 | 0.00 | - |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -131.146 | -152.446 | -439.493 | -375.113 | -311.988 | -10.86 | -4.441 | -3.6157 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 0 | 0 | 0 | 0 | 0 | 3 | 7 | - | 14 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -5.474 | -1.83 | -1.802 | -1.043 | -1.091 | -1.352 | -0.865 | -0.954 | -0.445 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 1 | 3 | 3 | 4 | 5 | 6 | 7 | 12 | 14 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.45 | 0.54-16.9% | 0.65+12.1% | 0.58-6.5% | 0.62-23.5% | 0.81-3.6% | 0.84+366.7% | 0.18 |
| Gross Profit | -0.45 | -0.54 | -0.65 | -0.58 | -0.62 | -0.81 | -0.84 | -0.18 |
| Selling, General and Administrative Excl. Other | 24.47 | 19.40+29.4% | 14.99-32.4% | 22.18+31.4% | 16.88-15.0% | 19.87+218.4% | 6.24-45.6% | 11.47 |
| Research and Development | 8.52 | 9.77+3.4% | 9.45-39.0% | 15.49+72.1% | 9.00+7.0% | 8.41+65.2% | 5.09-44.0% | 9.09 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -24.92 | -19.94 | -15.64 | -22.76 | -17.50 | -20.68 | -7.08 | -11.65 |
| Interest Expense | - | 0.92+1433.3% | 0.06 | - | - | 0.03-40.0% | 0.05 | 0.00 |
| Unusual Expense | 2.59 | 1.96+94.1% | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -28.80 | -22.45 | -16.56 | -23.53 | -17.68 | -20.71 | -7.18 | -11.55 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -28.80 | -22.45 | -16.56 | -23.53 | -17.68 | -20.71 | -7.18 | -11.55 |
| Net Income From Continuing Operations | -28.80 | -22.45 | -16.56 | -23.53 | -17.68 | -20.71 | -7.18 | -11.55 |
| Net Income | -28.81 | -22.45 | -16.56 | -23.53 | -17.68 | -20.71 | -7.18 | -11.55 |
| EPS (Recurring) per share | -2.05 | -4.17 | -10.39 | -311.99 | -375.11 | -439.49 | -152.45 | -131.15 |
| EPS (Basic, Before Extraordinaries) per share | -3.62 | -4.44 | -10.86 | -311.99 | -375.11 | -439.49 | -152.45 | -131.15 |
| EPS (Diluted) per share | -3.62 | -4.44 | -10.86 | -311.99 | -375.11 | -439.49 | -152.45 | -131.15 |
| EBITDA | -24.47 | -19.40 | -14.99 | -22.18 | -16.88 | -19.87 | -6.24 | -11.47 |
| Non-Operating Income (Expense) | -1.04 | 0.37+131.3% | 0.16 | -0.78 | -0.17 | 0.00 | -0.05-150.0% | 0.10 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.38 | 1.43+43.0% | 1.00+23.5% | 0.81+1.2% | 0.80+1900.0% | 0.04 | - | - |
| Shares Outstanding million shares | 13.89 | 7.25+113.2% | 3.40+3300.0% | 0.10+100.0% | 0.050.0% | 0.050.0% | 0.05-44.4% | 0.09 |
| Market Capitalization | 65.29 | 65.29+312.2% | 15.84+138.2% | 6.65-41.2% | 11.31-63.8% | 31.21+4.1% | 29.97 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.10-33.3% | 0.12-29.4% | 0.12-25.0% | 0.11-35.3% | 0.15-6.3% | 0.17+6.3% | 0.16-5.9% | 0.17+13.3% |
| Gross Profit | -0.10 | -0.12 | -0.12 | -0.11 | -0.15 | -0.17 | -0.16 | -0.17 |
| Selling, General and Administrative Excl. Other | 5.32+18.2% | 7.80+120.3% | 5.46-9.8% | 5.89+88.8% | 4.50+48.0% | 3.54+27.3% | 6.05-8.6% | 3.12-44.3% |
| Research and Development | 1.49-44.8% | 2.18-1.8% | 2.00-53.8% | 2.85+99.3% | 2.70+43.6% | 2.22+22.7% | 4.33-13.1% | 1.43-63.5% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.41 | -7.92 | -5.59 | -6.00 | -4.65 | -3.71 | -6.21 | -3.28 |
| Interest Expense | 0.24 | - | - | - | - | - | - | - |
| Unusual Expense | 0.47 | 1.19 | 0.58 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -5.87 | -9.31 | -6.27 | -7.34 | -4.79 | -3.80 | -6.13 | -3.23 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.87 | -9.31 | -6.27 | -7.34 | -4.79 | -3.80 | -6.13 | -3.23 |
| Net Income From Continuing Operations | -5.87 | -9.31 | -6.27 | -7.34 | -4.79 | -3.80 | -6.13 | -3.23 |
| Net Income | -5.87 | -9.32 | -6.27 | -7.34 | -4.79 | -3.80 | -6.13 | -3.23 |
| EPS (Recurring) per share | -0.42 | -0.87 | -0.81 | -1.31 | -1.09 | -1.04 | -1.80 | -1.83 |
| EPS (Basic, Before Extraordinaries) per share | -0.45 | -0.95 | -0.87 | -1.35 | -1.09 | -1.04 | -1.80 | -1.83 |
| EPS (Diluted) per share | -0.45 | -0.95 | -0.87 | -1.35 | -1.09 | -1.04 | -1.80 | -1.83 |
| EBITDA | -5.32 | -7.80 | -5.46 | -5.89 | -4.50 | -3.54 | -6.05 | -3.12 |
| Non-Operating Income (Expense) | 0.25 | -0.20 | -0.10-225.0% | -0.99-2080.0% | -0.14 | -0.10 | 0.08 | 0.05 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.36+300.0% | 0.73+102.8% | 0.29+61.1% | 0.00-100.0% | 0.09-64.0% | 0.36+125.0% | 0.18+20.0% | 0.39+62.5% |
| Shares Outstanding million shares | 13.89+184.0% | 11.91+211.0% | 7.25+113.2% | 5.98+96.7% | 4.89+526.9% | 3.83+811.9% | 3.40+3300.0% | 3.04+4242.9% |
| Market Capitalization | 65.29+277.8% | 72.21+422.9% | 29.33+85.2% | 21.22+93.1% | 17.28+980.0% | 13.81+978.9% | 15.84+138.2% | 10.99+28.5% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 10.95-10.3% | 12.21+24320.0% | 0.05-99.1% | 5.36-67.5% | 16.49+1274.2% | 1.20+172.7% | 0.44 |
| Short Term Receivables | 0.01-66.7% | 0.03+200.0% | 0.01-95.7% | 0.23-66.7% | 0.69+360.0% | 0.15+36.4% | 0.11 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.99+135.7% | 0.42+27.3% | 0.33-85.5% | 2.28+34.1% | 1.70+286.4% | 0.44+2.3% | 0.43 |
| Total Current Assets | 11.95-5.6% | 12.66+3065.0% | 0.40-94.9% | 7.87-58.3% | 18.88+954.7% | 1.79+82.7% | 0.98 |
| Net Property, Plant & Equipment | 3.07+39.5% | 2.20-24.4% | 2.91-17.8% | 3.54-11.5% | 4.000.0% | 4.00-3.8% | 4.16 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Other Assets | 0.06 | 0.00-100.0% | 0.18 | 0.00 | 0.00 | 0.00-100.0% | 0.14 |
| Total Assets | 15.07+1.4% | 14.86+325.8% | 3.49-69.4% | 11.41-50.2% | 22.89+295.3% | 5.79+9.7% | 5.28 |
| Short Term Debt Incl. Current Port. of LT Debt | 6.53+145.5% | 2.66-21.3% | 3.38-36.9% | 5.36+1629.0% | 0.31-73.5% | 1.17+120.8% | 0.53 |
| Accounts Payable | 2.04+60.6% | 1.27-75.6% | 5.20+584.2% | 0.76+192.3% | 0.26-73.5% | 0.98-48.4% | 1.90 |
| Other Current Liabilities | 1.74+67.3% | 1.04-37.0% | 1.65+85.4% | 0.89+48.3% | 0.60-50.8% | 1.22+134.6% | 0.52 |
| Total Current Liabilities | 10.31+107.4% | 4.97-51.4% | 10.23+45.9% | 7.01+494.1% | 1.18-64.9% | 3.36+13.9% | 2.95 |
| Long Term Debt | 2.25-7.8% | 2.44+1642.9% | 0.14-72.5% | 0.51-41.4% | 0.87-21.6% | 1.11-35.1% | 1.71 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02 | 0.00 |
| Total Liabilities | 12.56+69.5% | 7.41-28.5% | 10.36+37.8% | 7.52+268.6% | 2.04-54.7% | 4.50-3.4% | 4.66 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 2.51-66.4% | 7.46 | -6.87-277.1% | 3.88-81.4% | 20.84+1515.5% | 1.29+108.1% | 0.62 |
| Total Shareholders Equity | 2.51-66.4% | 7.46 | -6.87-277.1% | 3.88-81.4% | 20.84+1515.5% | 1.29+108.1% | 0.62 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 2.51-66.4% | 7.46 | -6.87-277.1% | 3.88-81.4% | 20.84+1515.5% | 1.29+108.1% | 0.62 |
| Total Liabilities & Stockholders Equity | 15.07+1.4% | 14.86+325.8% | 3.49-69.4% | 11.41-50.2% | 22.89+295.3% | 5.79+9.7% | 5.28 |
| Book Value Per Share per share | 0.35-84.0% | 2.19 | -70.61-185.7% | 82.38-81.4% | 442.33+1512.6% | 27.43+291.9% | 7.00 |
| Tangible Book Value Per Share per share | 0.35-84.0% | 2.19 | -70.61-185.7% | 82.38-81.4% | 442.33+1512.6% | 27.43+291.9% | 7.00 |
| Full-Time Employees people | 14+7.7% | 130.0% | 13-13.3% | 15-6.3% | 16 | - | - |
| Price to Book Ratio ratio | 2.66 | 1.25 | -69.00 | 1.35 | - | - | - |
| Return on Assets % | -149.98 | -180.43 | -315.98 | -103.09 | -144.45 | -129.80 | - |
| Return on Equity % | -450.60 | -5,651.01 | - | -142.98 | -187.12 | -752.88 | - |
| Return on Invested Capital % | -471.57 | -167.40 | - | -402.44 | -95.40 | -299.01 | -495.65 |
| Quick Ratio ratio | 1.16 | 2.55 | 0.04 | 1.12 | 16.05 | 0.53 | 0.33 |
| Current Ratio ratio | 1.16 | 2.55 | 0.04 | 1.12 | 16.05 | 0.53 | 0.33 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -29.04 | -22.45 | -16.56 | -23.53 | -17.68 | -20.71 | -7.18 | -11.55 |
| Depreciation | 0.45 | 0.54-16.9% | 0.65+12.1% | 0.58-6.5% | 0.62-23.5% | 0.81-3.6% | 0.84+366.7% | 0.18 |
| Other Funds (Non Cash) | 5.97 | 3.83+90.5% | 2.01+148.1% | 0.81+1.2% | 0.80-93.7% | 12.78 | 0.00 | -0.05 |
| Funds from Operations | -22.62 | -18.08 | -13.90 | -22.14 | -16.25 | -7.12 | -6.34 | -11.42 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.97 | 0.83 | -4.55-164.1% | 7.10+1818.9% | 0.37 | -3.31 | -0.47-118.0% | 2.61 |
| Cash from Operating Activities | -20.65 | -17.25 | -18.45 | -15.03 | -15.88 | -10.43 | -6.81 | -8.81 |
| Capital Expenditures | -0.28 | -0.16 | -0.21 | -0.22 | -0.15 | -0.81 | -0.40 | -1.02 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02-99.5% | 3.76 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -1.55 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02-99.6% | 5.31 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.28 | -0.16 | -0.21 | -0.22 | -0.15 | -0.81 | -0.38-113.9% | 2.74 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 35.10 | 10.15-60.8% | 25.88+271.3% | 6.97 | -0.09-100.3% | 27.48+265.9% | 7.51 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 35.10 | 10.15-60.8% | 25.88+271.3% | 6.97 | -0.09-100.3% | 27.48+265.9% | 7.51 | 0.00 |
| Proceedsfrom Stock Options | 35.10 | 10.15-60.8% | 25.88+271.3% | 6.97 | -0.09-100.3% | 27.48+265.9% | 7.51 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 6.00+21.2% | 4.95+65.0% | 3.00-40.0% | 5.00 | -0.50-158.8% | 0.85 | -0.73 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 6.14 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 40.44 | 16.15-47.6% | 30.82+209.7% | 9.95+103.1% | 4.90-81.5% | 26.54+233.0% | 7.97+47.0% | 5.42 |
| Net Change in Cash | 19.50 | -1.26-110.4% | 12.16 | -5.30 | -11.14-172.8% | 15.30+1861.5% | 0.78 | -0.64 |
| Free Cash Flow | -20.94 | -17.41 | -18.66 | -15.26 | -16.04 | -11.25 | -7.21 | -9.82 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 28.40+219.1% | 25.89+172.0% | 10.95-10.3% | 6.12-39.0% | 8.90+2242.1% | 9.52+757.7% | 12.21+24320.0% | 10.04+404.5% |
| Short Term Receivables | 0.04+100.0% | 0.05+25.0% | 0.01-66.7% | 0.02 | 0.02-98.8% | 0.04 | 0.03+200.0% | 0.00-100.0% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.77+36.2% | 1.97+109.6% | 0.99+135.7% | 1.30+0.8% | 1.30+188.9% | 0.94-41.6% | 0.42+27.3% | 1.29+41.8% |
| Total Current Assets | 30.21+195.6% | 27.91+165.8% | 11.95-5.6% | 7.43-34.4% | 10.22+317.1% | 10.50+284.6% | 12.66+3065.0% | 11.33+290.7% |
| Net Property, Plant & Equipment | 2.86-12.0% | 2.95+50.5% | 3.07+39.5% | 3.09+37.9% | 3.25+24.5% | 1.96-29.2% | 2.20-24.4% | 2.24-24.6% |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.06 | 0.00-100.0% | 0.00-100.0% | 0.00 | 0.00-100.0% | 0.01 |
| Total Assets | 33.07+145.5% | 30.86+147.5% | 15.07+1.4% | 10.52-22.5% | 13.47+162.6% | 12.47+127.1% | 14.86+325.8% | 13.58+131.3% |
| Short Term Debt Incl. Current Port. of LT Debt | 5.32-0.7% | 6.39+53.6% | 6.53+145.5% | 3.42+1387.0% | 5.36+1524.2% | 4.16+966.7% | 2.66-21.3% | 0.23-93.2% |
| Accounts Payable | 1.99+128.7% | 2.67+210.5% | 2.04+60.6% | 0.87-4.4% | 0.87-34.6% | 0.86+16.2% | 1.27-75.6% | 0.91-45.5% |
| Other Current Liabilities | 1.32+164.0% | 1.90+216.7% | 1.74+67.3% | 1.60+300.0% | 0.50+31.6% | 0.60-46.4% | 1.04-37.0% | 0.40-42.0% |
| Total Current Liabilities | 8.63+28.2% | 10.96+95.0% | 10.31+107.4% | 5.88+281.8% | 6.73+229.9% | 5.62+149.8% | 4.97-51.4% | 1.54-73.1% |
| Long Term Debt | 0.97-20.5% | 1.04+13.0% | 2.25-7.8% | 1.16 | 1.22 | 0.92+2966.7% | 2.44+1642.9% | 0.00-100.0% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.60+20.6% | 12.00+83.5% | 12.56+69.5% | 7.05+357.8% | 7.96+290.2% | 6.54+186.8% | 7.41-28.5% | 1.54-74.2% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 23.47+326.0% | 18.86+218.0% | 2.51-66.4% | 3.47-71.2% | 5.51+78.9% | 5.93+84.2% | 7.46 | 12.04 |
| Total Shareholders Equity | 23.47+326.0% | 18.86+218.0% | 2.51-66.4% | 3.47-71.2% | 5.51+78.9% | 5.93+84.2% | 7.46 | 12.04 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 23.47+326.0% | 18.86+218.0% | 2.51-66.4% | 3.47-71.2% | 5.51+78.9% | 5.93+84.2% | 7.46 | 12.04 |
| Total Liabilities & Stockholders Equity | 33.07+145.5% | 30.86+147.5% | 15.07+1.4% | 10.52-22.5% | 13.47+162.6% | 12.47+127.1% | 14.86+325.8% | 13.58+131.3% |
| Book Value Per Share per share | 1.69+49.6% | 1.58+1.9% | 0.35-84.0% | 0.58-85.3% | 1.13-71.4% | 1.55-79.9% | 2.19 | 3.95 |
| Tangible Book Value Per Share per share | 1.69+49.6% | 1.58+1.9% | 0.35-84.0% | 0.58-85.3% | 1.13-71.4% | 1.55-79.9% | 2.19 | 3.95 |
| Full-Time Employees people | - | - | 14+7.7% | - | - | - | 130.0% | - |
| Price to Book Ratio ratio | 2.66 | 17.95 | 7.47 | 3.48 | 2.63 | 1.96 | 1.25 | 1.28 |
| Return on Assets % | -123.76 | -127.92 | -148.34 | -183.12 | -193.12 | -182.32 | -169.38 | -168.10 |
| Return on Equity % | -198.74 | -223.55 | -445.69 | -284.50 | -417.77 | -358.06 | -5,305.02 | -273.82 |
| Return on Invested Capital % | -24.02 | -46.79 | -131.77 | -158.33 | -71.10 | -55.48 | -61.99 | -26.85 |
| Quick Ratio ratio | 3.50 | 2.55 | 1.16 | 1.26 | 1.52 | 1.87 | 2.55 | 7.34 |
| Current Ratio ratio | 3.50 | 2.55 | 1.16 | 1.26 | 1.52 | 1.87 | 2.55 | 7.34 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -5.87 | -9.31 | -6.27 | -7.59 | -4.79 | -3.80 | -6.13 | -3.23 |
| Depreciation | 0.10-33.3% | 0.12-29.4% | 0.12-25.0% | 0.11-35.3% | 0.15-6.3% | 0.17+6.3% | 0.16 | 0.17-22.7% |
| Other Funds (Non Cash) | 0.92+240.7% | 1.94+340.9% | 0.98+1533.3% | 2.13+446.2% | 0.27-28.9% | 0.44+175.0% | 0.06-60.0% | 0.39+62.5% |
| Funds from Operations | -4.86 | -7.25 | -5.17 | -5.34 | -4.37 | -3.20 | -5.91 | -2.67 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -1.04 | 0.34 | 1.57-14.2% | 1.10 | -0.43-146.2% | -1.41 | 1.83-56.8% | -1.21-198.4% |
| Cash from Operating Activities | -5.90 | -6.91 | -3.60 | -4.24 | -4.80 | -4.61 | -4.08 | -3.88 |
| Capital Expenditures | -0.07 | -0.06 | -0.16 | 0.00-100.0% | -0.01 | 0.00 | -0.20 | 0.14 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.07 | -0.06 | -0.16 | 0.00-100.0% | -0.01 | 0.00 | -0.20 | 0.14 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 9.14+118.7% | 21.91+1041.1% | 2.59+73.8% | 1.46-89.1% | 4.18+283.5% | 1.92-80.6% | 1.49+81.7% | 13.41+126.1% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 9.14+118.7% | 21.91+1041.1% | 2.59+73.8% | 1.46-89.1% | 4.18+283.5% | 1.92-80.6% | 1.49+81.7% | 13.41+126.1% |
| Proceedsfrom Stock Options | 9.14+118.7% | 21.91+1041.1% | 2.59+73.8% | 1.46-89.1% | 4.18+283.5% | 1.92-80.6% | 1.49+81.7% | 13.41+126.1% |
| Issuance or Reduction of Debt, Net | -0.66 | 0.00 | 6.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 8.48+102.9% | 21.91+1041.1% | 8.59+33.2% | 1.46-89.1% | 4.18+287.0% | 1.92-80.6% | 6.45+686.6% | 13.40+126.0% |
| Net Change in Cash | 2.51 | 14.94 | 4.83+122.6% | -2.78-128.8% | -0.62 | -2.69-353.8% | 2.17 | 9.66+489.0% |
| Free Cash Flow | -5.97 | -6.97 | -3.75 | -4.24 | -4.80 | -4.61 | -4.28 | -3.74 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 8.55% | 1.0M | 12.1M | 121.13K |
| 2026-10-15 | 8.38% | 1.0M | 12.1M | 125.86K |
| 2026-09-30 | 8.50% | 1.0M | 12.1M | 167.99K |
| 2026-09-15 | 9.64% | 1.2M | 12.1M | 214.29K |
| 2026-08-31 | 8.83% | 1.1M | 12.0M | 360.91K |
| 2026-08-14 | 10.07% | 1.2M | 12.0M | 437.67K |
| 2026-07-31 | 14.18% | 1.6M | 11.1M | 483.80K |
| 2026-07-15 | 15.16% | 1.7M | 11.1M | 553.84K |
| 2026-06-30 | 12.47% | 1.4M | 11.0M | 556.85K |
| 2026-06-15 | 15.97% | 1.8M | 11.0M | 652.51K |
| 2026-05-29 | 18.09% | 2.0M | 10.8M | 564.79K |
| 2026-05-15 | 14.88% | 1.6M | 10.6M | 519.27K |
| 2026-04-30 | 15.29% | 1.5M | 9.8M | 514.02K |
| 2026-04-15 | 14.53% | 1.4M | 9.8M | 493.05K |
| 2026-03-31 | 13.20% | 1.1M | 8.2M | 473.33K |
| 2026-03-13 | 6.38% | 0.5M | 8.2M | 320.63K |
| 2026-02-27 | 8.53% | 0.5M | 5.4M | 268.58K |
| 2026-02-13 | 7.61% | 0.4M | 5.4M | 238.30K |
| 2026-01-30 | 5.32% | 0.4M | 7.3M | 197.45K |
| 2026-01-15 | 3.69% | 0.3M | 7.3M | 177.44K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.30 | 4.90 | 1.90 | 0.000 | 9.00 | 0.00 | 0.947 | -0.013 | 0.001 |
| call | 5.00 | 0.00 | 0.45 | 0.30 | 2.442 | 1,549 | 0.00 | 0.453 | -0.041 | 0.003 |
| call | 7.50 | 0.00 | 0.50 | 0.05 | 4.191 | 374 | 0.00 | 0.341 | -0.063 | 0.003 |
| call | 10.00 | 0.00 | 4.90 | 1.05 | 5.562 | 76.00 | 0.00 | 0.284 | -0.079 | 0.002 |
| call | 12.50 | 0.00 | 0.20 | 0.05 | 6.048 | 78.00 | 0.00 | 0.279 | -0.083 | 0.002 |
| put | 2.50 | 0.00 | 0.05 | 0.03 | 2.793 | 1,361 | 0.00 | -0.050 | -0.012 | 0.001 |
| put | 5.00 | 0.00 | 1.00 | 0.70 | 2.612 | 619 | 0.00 | -0.547 | -0.040 | 0.003 |
| put | 7.50 | 0.80 | 5.50 | 4.10 | 12.715 | 0.00 | 0.00 | -0.678 | -0.066 | 0.002 |
| put | 10.00 | 3.00 | 7.70 | 6.40 | 12.534 | 1.00 | 0.00 | -0.716 | -0.078 | 0.002 |
| put | 12.50 | 5.60 | 10.50 | 10.00 | 14.671 | 0.00 | 0.00 | -0.845 | -0.049 | 0.002 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | 8-K | Current report | 2026-11-10 | SEC |
| 2026-10-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-30 | SEC |
| 2026-10-02 | 8-K | Current report | 2026-09-30 | SEC |
| 2026-08-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-13 | 8-K | Current report | 2026-08-13 | SEC |
| 2026-07-23 | 8-K | Current report | 2026-07-17 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-20 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-16 | SEC |
| 2026-07-15 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-07-14 | 8-K | Current report | 2026-07-09 | SEC |
| 2026-07-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-30 | SEC |
| 2026-07-02 | 8-K | Current report | 2026-06-30 | SEC |
| 2026-06-16 | 8-K | Current report | 2026-06-16 | SEC |
| 2026-06-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-02-13 | SEC |
| 2026-06-08 | 3 | Initial statement of beneficial ownership of securities | 2026-02-13 | SEC |
| 2026-06-02 | 8-K | Current report | 2026-06-02 | SEC |
| 2026-05-29 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-05-29 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-05-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-29 | SEC |
| 2026-05-19 | 8-K | Current report | 2026-05-18 | SEC |
| 2026-05-18 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-05-18 | SEC |
| 2026-05-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-14 | 8-K | Current report | 2026-05-14 | SEC |
| 2026-05-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-31 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 656.96K | 5 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 4.24% |
| RAYMOND JAMES FINANCIAL INC | 1.48% |
| RENAISSANCE TECHNOLOGIES LLC | 1.28% |
| Kestra Advisory Services, LLC | 1.08% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.05% |
| BOLTON SECURITIES CORPORATION | 0.96% |
| Chicago Partners Investment Group LLC | 0.76% |
| North Star Investment Management Corp. | 0.69% |
| VANGUARD FIDUCIARY TRUST CO | 0.59% |
| SIMPLEX TRADING, LLC | 0.49% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.93% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.19% |
| Fidelity Extended Market Index Fund | 0.49% |
| iShares Micro-Cap ETF | 0.21% |
| Fidelity Total Market Index Fund | 0.15% |
| Fidelity Series Total Market Index Fund | 0.15% |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND | 0.08% |
| Fidelity Nasdaq Composite Index Fund | 0.06% |
| VANGUARD BALANCED INDEX FUND | 0.04% |
| 1290 VT Micro Cap Portfolio | 0.01% |
OakChart. CING. Cached 15 minutes. Terms